Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"Remember trading rules and rules for shorting in particular only apply to the individual retail trader."
Finally, thank you blueboy1, big boys only cover when they win, and they only win, yes its all rigged.....
The next significant event for Exact Sciences should be publication of the Cologuard pivotal "Deep-C" validation study in a medical journal before the FDA advisory panel on March 27.
Not an AF fan, but here you go,
http://www.thestreet.com/story/12520475/1/biotech-stock-mailbag-exact-sciences-rexahn-advaxis-peregrine.html
Yeah, I own it and I can't wait to use it instead of going to the roto rooter, cause I'm over due:)
Four Reasons Why Apple Should Buy Nokia
http://beta.fool.com/leokornsun/2013/02/11/four-reasons-why-apple-should-buy-nokia/24069/
watch for the champagne delivery truck
must of had offering birth pains:)
Will subscribing to ihub premium remove the ads?
$18.53 premarket?
date is Jan 7th 2013?
..."but the next report better be a good one." I'll bet it will be a good report, but "forward guidance" is what I am afraid they will use to tank it after the run up.
Great site, thank you.
I agree with you poop deck, apple will have a great quarter. Forward guidance is what they will use to dampen the rally I fear....unless we get a "don't bet against us" surprise.
"III expect $ARIA to close right around $21.50 area today"....nice call:)
I expected the drop below $25 Friday. What was surprising to me was the late day surge to $25.80, did not see that coming, we usually tank a bit. Will add at the next down spike.
that is the most comprehensive chart coverage I have seen....hope that all equals a buy...cause I just bought at $22.05 yesterday:)
"vanadium sources"...Looks like they are mostly Canadian mining companies on the Toronto exchange. Do you know of any US stock exchange traded vanadium source companies?
NEW YORK, May 13, 2011 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA - News), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, announced today that it has signed a contract with the Biomedical Advanced Research and Development Authority (BARDA) of the United States Department of Health and Human Services (HHS) to deliver two million courses of its smallpox antiviral, ST-246(R), to the Strategic National Stockpile. The 5-year base contract award is worth $433 million and includes options that would raise the contract's total value to approximately $2.8 billion, if these options are fully exercised. Contract options include the delivery of up to 12 million additional courses of ST-246(R).
"BARDA's selection of ST-246(R) for the Strategic National Stockpile underscores the U.S. government's commitment to Project BioShield and the procurement of medical countermeasures to address the threat of a smallpox attack," stated Dr. Eric A. Rose, SIGA's Chairman and Chief Executive Officer. "The contract award confirms SIGA's status as a leader in the biodefense industry and highlights our abilities in drug discovery, development and commercialization. Within just five years of the first non-human primate trial for ST-246(R), we are getting ready to deliver the world's first completely new small-molecule drug to address a major bioterrorism threat and one of the most lethal diseases in history. We value our new role as a provider of biodefense countermeasures to the U.S. government, which is the culmination of years of successful research and development collaborations with the U.S. government that have enabled us to take this drug to the commercial stage. We believe this keystone contract is a historic event for the biodefense industry and will be the first of many commercial successes for ST-246(R) here and around the world."
Under the contract, SIGA will deliver 1.7 million courses of ST-246(R). Additionally, SIGA will contribute 300,000 courses manufactured using federal funds provided by HHS under prior development contracts. In addition to the option to purchase up to an additional 12 million courses, the contract will also permit SIGA to continue its work on pediatric and geriatric versions of the drug as well as use of ST-246(R) for smallpox prophylaxis. Dr. Rose added, "We believe that the funding to extend ST-246(R) to these vulnerable populations is critical to the future success of the U.S. government's smallpox biodefense efforts. There are approximately 64 million children in the United States (through age 15), none of whom is currently vaccinated against this disease."
SIGA's groundbreaking drug, ST-246(R), is an oral therapeutic agent active against orthopoxviruses including smallpox. While no longer present naturally in the environment, smallpox is considered a formidable bioterrorism threat, and there is currently no FDA-approved treatment for symptomatic individuals. ST-246(R) works by blocking the ability of the virus to spread to other cells, preventing it from causing disease. The FDA has designated ST-246(R) for "fast-track" status, creating a path for expedited FDA review and eventual regulatory approval.
Saw this last month, makes sense...a spokesman for Ford noted that U.S. pickup sales are getting a boost from rising farm incomes.
$12.47 still undervalued
vaccine? i dont think so, antiviral it is............